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Abstract
Background: Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen that stimulates vasculogenesis. 
It has also been shown to act as a neurotrophic factor in vitro and in vivo. Deletion of the hypoxia response element of 
the promoter region of the gene encoding VEGF in mice causes a reduction in neural VEGF expression, and results in 
adult-onset motor neurone degeneration that resembles amyotrophic lateral sclerosis (ALS). Investigating the 
molecular pathways to neurodegeneration in the VEGFδ/δ mouse model of ALS may improve understanding of the 
mechanisms of motor neurone death in the human disease.
Results: Microarray analysis was used to determine the transcriptional profile of laser captured spinal motor neurones 
of transgenic and wild-type littermates at 3 time points of disease. 324 genes were significantly differentially expressed 
in motor neurones of presymptomatic VEGFδ/δ mice, 382 at disease onset, and 689 at late stage disease. Massive 
transcriptional downregulation occurred with disease progression, associated with downregulation of genes involved 
in RNA processing at late stage disease. VEGFδ/δ mice showed reduction in expression, from symptom onset, of the 
cholesterol synthesis pathway, and genes involved in nervous system development, including axonogenesis, synapse 
formation, growth factor signalling pathways, cell adhesion and microtubule-based processes. These changes may 
reflect a reduced capacity of VEGFδ/δ mice for maintenance and remodelling of neuronal processes in the face of 
demands of neural plasticity. The findings are supported by the demonstration that in primary motor neurone cultures 
from VEGFδ/δ mice, axon outgrowth is significantly reduced compared to wild-type littermates.
Conclusions: Downregulation of these genes involved in axon outgrowth and synapse formation in adult mice 
suggests a hitherto unrecognized role of VEGF in the maintenance of neuronal circuitry. Dysregulation of VEGF may 
lead to neurodegeneration through synaptic regression and dying-back axonopathy.
Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disorder in which selective loss of motor neurones
in the cerebral cortex, brainstem and spinal cord leads to
progressive paralysis. In the majority of cases of ALS, the
cause of motor neurone degeneration is unknown,
although a number of pathogenic processes, including
oxidative stress, excitotoxicity, inflammation, and mito-
chondrial and neurofilament dysfunction, are thought to
play important roles. Ten percent of cases of ALS are
familial, and in 20% of these, a causative mutation is
found in the gene encoding superoxide dismutase I
(SOD1), a free radical scavenger. In the SOD1 rodent
model of ALS, overexpression of human mutant SOD1
causes adult onset motor neurone degeneration.
Vascular endothelial growth factor (VEGF) is an
endothelial cell mitogen that stimulates angiogenesis in
response to hypoxia, in the developing embryo and in a
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Page 2 of 29number of pathological conditions, such as tumour
growth. VEGF transcription is upregulated by binding of
hypoxia inducible factor (HIF-1) to a hypoxia response
element (HRE) in the 5' promoter region of the gene. In
2001, Oosthuyse et al deleted the HRE of the VEGF gene
in mice, to generate VEGFδ/δ mice [1], which express
reduced levels of Vegf in neural tissue under both base-
line and hypoxic conditions. VEGFδ/δ mice show 60%
mortality at or around birth, and surviving transgenic
mice are slightly smaller than their wild-type littermates.
At 5 months of age, they develop a motor neurodegenera-
tive phenotype that resembles ALS, with impairment of
motor behaviours and motor tests, such as the treadmill
test. Electrophysiological studies show signs of denerva-
tion and compensatory reinnervation, muscle histology
shows neurogenic atrophy, and peripheral nerves show
loss of large myelinated motor axons. In the spinal cord
and brainstem, similar numbers of motor neurones are
present until 3 months of age, but by 17 months, there is a
30% reduction in motor neurone numbers, with a reac-
tive astrocytosis, and neurofilament inclusions in surviv-
ing neurones [1]. The mechanism of neurodegeneration
in VEGFδ/δ mice is unknown. Chronic hypoxia has been
proposed, as although vascular structure in the sciatic
nerve and spinal cord is normal, baseline neural blood
flow is reduced by 44%. In addition to vascular develop-
ment, however, VEGF plays a central role in the develop-
ment of the nervous system, and may be required for
survival of adult neurones [2]. Disruption of these func-
tions may determine the development of neuronal degen-
eration in VEGFδ/δ mice.
VEGF has neurotrophic effects in vitro in a wide range
of culture conditions, promoting cell survival and neurite
outgrowth, via its tyrosine kinase receptor, VEGFR2 [3].
In vivo, VEGF administration prolongs survival in the
SOD1 model of ALS [4]. This is likely to be a direct neu-
roprotective effect, as SOD1 mice crossed with mice with
neuronal overexpression of VEGFR2 also exhibit delayed
disease progression [5]. In the developing nervous sys-
tem, VEGF released by neuroblasts and glia induces the
ingrowth of capillaries, and deletion of a single copy of
VEGF is lethal [6,7]. VEGF stimulates neurogenesis
directly [8], and via endothelial cell proliferation, to form
vascular niches in which neurogenesis is stimulated by
endothelial-derived BDNF [9,10]. Further interaction
between vascular and neuronal development is seen in
the closely aligned growth of blood vessels and peripheral
nerves, directed by attractive and repulsive cues on the
growth cone [11]. The VEGF co-receptor, Neuropilin-1
mediates both repulsive signals of the semaphorin family,
and attractant signals of VEGF [11,12]. Thus VEGF, with
its angiogenic and neurotrophic actions via VEGFR2, and
shared receptor with the semaphorin axon guidance fac-
tors, may be a key player in the parallel development of
vascular and nervous systems.
A recent meta-analysis of association studies of VEGF
polymorphisms with ALS showed an increased risk of
ALS in male patients with the -2578AA genotype, which
lowers VEGF expression[13]. We have previously shown
that levels of expression of VEGF and its main agonist
receptor are reduced in the spinal cord of patients with
ALS[14]. This study aims to clarify the molecular mecha-
nisms of neurodegeneration in the VEGFδ/δ mouse, by
determination of the transcriptional profile of isolated
spinal motor neurones in the transgenic mouse, com-
pared to its wild type littermate. Understanding the role
of VEGF in the survival and death of motor neurones in
this mouse model of ALS may have implications for the
human disease.
We report that adult VEGFδ/δ mice show reduction in
expression, from symptom onset, of genes involved in
nervous system development, particularly in axonogene-
sis and synapse formation, and that axon outgrowth is
reduced in motor neurone cultures derived from VEGFδ/δ
mice. These changes suggest a role for VEGF in the main-
tenance of neuronal circuitry, disruption of which may
result in a dying-back axonopathy.
Methods
Experimental animals
Adult female VEGFδ/δ mice and wild type littermates
(Vesalius Research Institute, Leuven, Belgium) were used
in this study. VEGFδ/δ mice, on a Swiss/129 background,
had homozygous deletion of the HIF-1 response element
(hypoxia response element) in the promoter region of the
VEGF gene, and were generated as previously described
[1]. All mice were housed in conventional facilities with a
12 h light/dark cycle with access to food at libitum. The
local animal ethical committee, the Ethische Commissie
Dierproeven (ECD) at the Catholic University Leuven,
Belgium, approved the VEGFδ/δ mouse experiments.
Tissue collection
Three female VEGFδ/δ transgenic mice, and three gender-
matched wild-type littermate controls were sacrificed at 3
months (pre-symptomatic), 5 months (onset of symp-
toms) and 14 months (late stage disease) of age, by over-
dose of isoflurane inhalational anaesthetic. Post mortem,
animals were perfused by intracardiac injection of 15 ml
sterile phosphate buffer with 30% sucrose, and the CNS
was dissected and frozen in Cryo-M-Bed embedding
compound (Bright, Huntingdon, UK). The procedure of
sucrose perfusion and dissection of the spinal cord was
conducted rapidly, within a maximum of ten minutes
from terminal anaesthesia to snap freezing of tissue, to
ensure optimal preservation of RNA quality. Lumbar spi-
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washed in DEPC-treated water, and stained for 1 minute
in a solution of 0.1% w/v Toluidine Blue in 0.1 M sodium
phosphate. They were then washed and dehydrated
through graded ethanol concentrations (70, 90 and
100%), and xylene.
Laser capture microdissection, RNA isolation and 
amplification
Spinal motor neurones, identified by staining, anatomical
location, size and morphology, were isolated on Capsure
Macro LCM caps using the Arcturus PixCell II laser cap-
ture microdissection system (Arcturus Bioscience,
Mountain View, CA). Approximately 1500 motor neu-
rones were dissected from each spinal cord, and >50 ng
RNA extracted using the PicoPure™ RNA isolation kit
(Arcturus), according to manufacturer's instructions.
RNA amplification was carried out using a linear amplifi-
cation process in 2 cycles, with the GeneChip two cycle
target labelling and control kit (Affymetrix, Santa Clara,
USA), and MEGAscript® T7 kit (Ambion, Austin, USA).
The linear amplification technique has been shown to
generate highly reproducible gene expression profiles
from small starting quantities of RNA [15]. This proce-
dure produced 50-100 μg of biotin labelled antisense
RNA for each sample, the quality and quantity of which
was assayed using the Agilent bioanalyser and Nano-
drop™ 1000 spectrophotometer (Thermo Scientific,
Wilmington, USA).
Quality control parameters
At each stage of extraction, amplification and microarray
analysis, we carried out quality control (QC) measures,
according to Affymetrix protocols, to ensure that RNA
was of sufficient quality and was matched between sam-
ples. Where QC outliers were identified, these samples
were excluded from the analysis. We used visual interpre-
tation of RNA profiles from bioanalyser traces of
extracted and amplified RNA to determine RNA quality,
as the 28S:18S ratio has been shown to have only weak
correlation with gene expression levels in downstream
experiments[16]. The RNA profiles obtained from laser
captured material in this study were comparable to pro-
files with modest RNA degradation, that has been shown
to have little effect on the results of microarray analysis
[17,18] (Figure 1) Following amplification, the most fre-
quent length of RNA amplicons, at 500-1000 kB, was con-
sistent with Affymetrix protocols. Affymetrix and
Bioconductor software was used to generate, from
microarray data, the QC measures of average back-
ground, signal intensity, percent present calls, and RNA
degradation plots, to ensure that samples were compara-
ble in all parameters.
Affymetrix GeneChip processing
15 μg amplified cRNA was fragmented by heating to 94°C
for 20 minutes, and spiked hybridization controls were
added. Each sample was hybridized to one mouse 430A2
GeneChip (Affymetrix) according to manufacturer's pro-
tocols. Following overnight hybridization at 42°C,
GeneChips underwent stringency washes in a Fluidics
Station 400, then were scanned in the GeneChip Scanner
3000 to detect fluorescent hybridization signals. These
were analysed by the Affymetrix GeneChip Operating
System (GCOS) to generate an overall hybridization sig-
nal for each transcript from 11 representative perfect
match and mismatch probe pairs.
Microarray data analysis
CEL files generated by GCOS were imported for further
analysis into Array Assist software (Stratagene, La Jolla,
USA), where probe level analysis was carried out using
the GC Robust Multichip Average (GC-RMA) algorithm.
Following GCRMA processing, data was filtered to
remove those genes whose expression was at or around
the background signal level of the chip. Any probe set
that returned a signal of <50 on more than 3 chips at each
time point was excluded from further analysis. This sig-
nal filter did not remove genes that were only expressed
in one experimental group. Differential gene expression
was determined using an unpaired t-test, to generate a list
of genes that were significantly differentially expressed
between transgenic mice and their wild type littermates,
at each time point.
Gene ontology analysis
Gene Ontology (GO) terms that reflect the function of
the corresponding genes are assigned to each probe set by
Affymetrix software. This GO information was used to
determine which functionally related groups of genes
were over-represented amongst significantly differen-
tially expressed genes at each time point. The frequencies
of GO terms represented in the significant gene lists were
compared to a denominator list of genes that can be
expressed by motor neurones in health or disease. GO
analysis was carried out without regard for fold change, in
order to limit type II errors and in order to detect more
subtle changes in gene expression, for example in tran-
scriptional regulators, which may be biologically signifi-
cant. The denominator list was generated from the array
data for each time point, by extracting those genes whose
representative probe sets returned a signal of >50 in 3 or
more chips. Statistical analysis of GO term enrichment
was carried out using DAVID software (NIAID/NIH;
http://david.abcc.ncifcrf.gov/summary.jsp, [19]. Litera-
ture review was also used to identify significantly differ-
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identified as enriched by DAVID analysis.
Verification of microarray results by Quantitative rt-PCR 
(QPCR)
A proportion of genes identified as significantly differen-
tially expressed were selected for verification by QPCR,
on the basis of robust microarray data confirming differ-
ential gene expression, involvement in a biological pro-
cess identified as enriched by GO analysis, or a known
function in neurodegeneration. Verification addresses the
possibility of false positive microarray signals, due to
cross-hybridization with related genes, concern about the
accuracy of array probe sets, and uncertainty about the
hybridization kinetics of multiple reactions occurring on
the miniature scale of an array chip. RNA was extracted
from 1000-1500 cells, isolated by laser capture microdis-
section from the lumbar spinal cord of the population of
mice used in the microarray experiment and, where avail-
able, a second population of transgenic mice with wild-
type littermates. RNA was extracted, quantified as previ-
ously described, and reverse transcribed to cDNA using
Superscript II reverse transcriptase, according to manu-
facturer's protocol (Invitrogen, San Diego, CA). Primers
used in for verification are shown in Table 1. QPCR was
performed using 12.5 ng cDNA, 1×SYBR Green PCR
master mix (Applied Biosystems, Foster City, CA), and
forward and reverse primers at optimized concentra-
tions, to a total volume of 20 μl. After an initial denatur-
ation at 95°C for 10 mins, templates were amplified by 40
cycles of 95°C for 15 secs and 60°C for 1 minute, on an
MX3000P Real-Time PCR system (Stratagene). A dissoci-
ation curve was then generated to ensure amplification of
a single product, and absence of primer dimers. For each
primer pair, a standard curve was generated to determine
the efficiency of the PCR reaction over a range of tem-
plate concentrations from 0.3 ng/μl to 25 ng/μl, using
cDNA synthesized from mouse universal RNA. The effi-
ciency for each set of primers was 100+/-10%, such that
gene expression values, normalized to ß-actin expression,
could be determined using the ddCt calculation (ABI
PRISM 7700 Sequence Detection System protocol;
Applied Biosystems). An unpaired t-test was used to
determine the statistical significance of any differences in
gene expression. β-actin hybridization signals deter-
mined by microarray analysis confirmed that there was
no significant difference in β-actin expression between
wild type and transgenic mice. To determine the effect of
the choice of the normalizing gene on the verification of
microarray results by QPCR, the expression of four genes
was also determined using two alternative normalizing
genes, HspB8 and Nme1. These were identified by
microarray analysis as having the most consistent levels
of expression in spinal motor neurones at each time
point, with the lowest coefficient of variation of hybrid-
ization signals.
Neural VEGF quantitation
Ten 10 μm sections of cervical cord were taken from each
mouse used in the microarray study. RNA was extracted
using the PicoPure™ RNA isolation kit (Arcturus) and
reverse transcribed to cDNA with Superscript II reverse
transcriptase (Invitrogen), according to manufacturer's
protocols. Neural VEGF expression was assessed by
QPCR, as described above, normalized to the expression
of ß-actin. Primer sequences and concentrations are
shown in Table 1. VEGF expression was compared
between VEGFδ/δ and wild-type mice using an unpaired t
test.
Figure 1 Representative bioanalyser traces of RNA samples pre- and post-amplification at 3 months, 5 months and 14 months.
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of axonal outgrowth
Cultures of spinal motor neurons from E12.5 mice (VEG-
Fwt/wt, n = 8; VEGFδ/wt, n = 14; and VEGFδ/δ, n = 4) were
prepared by a panning technique using a monoclonal
anti-p75NTR antibody (Millipore Bioscience Research
Reagents)[20]. The ventrolateral parts of individual lum-
bar spinal cords were dissected and transferred to HBSS
containing 10 mM 2-mercaptoethanol. After treatment
with trypsin (0.05%, 10 min), single cell suspensions were
generated by titration. The cells were plated on an anti-
p75NTR coated culture dish (24 well; Greiner) and left at
room temperature for 30 min. The individual wells were
subsequently washed with HBSS (three times), and the
attaching cells were then isolated from the plate with
depolarizing saline (0.8% NaCl, 35 mM KCl, and 1 mM 2-
mercaptoethanol) and plated at a density of 1500 cells per
well on laminin-coated coverslips in Greiner four-well
culture dishes. Motor neurons from single embryos were
cultured for 7 days in quadruplicates in the presence of
BDNF and CNTF (1 ng/ml each, 2000 cells/well initially).
Surviving neurons were counted on day 0, 1 and day 7.
Initial counting of plated cells was done when all cells
were attached to the culture dish at 4 h after plating. At
day 7, wells were fixed with fresh 4% paraformaldehyde in
phosphate buffer and subjected to immunocytochemis-
try. Two coverslips with motor neurons of each embryo
were stained with antibodies against MAP2 and P-Tau to
distinguish between axons and dendrites. Axon lengths of
VEGFwt/wt (n = 202), VEGFδ/wt, (n = 406) and VEGFδ/δ (n
= 122) neurones were measured using the Leica Confocal
Software (Leica, Germany), and compared using a t test.
Results
Neural VEGF expression
VEGFδ/δ mice used in this study showed a reduction in
expression of VEGF mRNA in the cervical spinal cord of
33% compared to their wild type littermates (data not
shown). A similar reduction in baseline spinal VEGF pro-
tein expression in the spinal cord, although not of mRNA
expression, was described by Oosthuyse et al [1].
General features of differential gene expression between 
VEGFδ/δ and wild type mice
Between 15 and 18% of probe sets at each time point
passed the signal filter, and their corresponding genes
were considered expressed by motor neurones. Statistical
analysis of these genes showed that 324 genes were signif-
icantly differentially expressed (at p < 0.05 level) between
VEGFδ/δ and wild type mice at 3 months, 382 genes at 5
months, and 689 genes at late stage. The total numbers of
genes which are upregulated and downregulated, with
three different p values (0.05, 0.01 and 0.001) are given for
each time point in Table 2. Prior to symptom onset, the
majority of differentially expressed genes were upregu-
lated. At disease onset, this pattern had reversed, and the
majority of genes were significantly downregulated. At
late stage disease there was marked transcriptional down-
regulation, shown in Figure 2. Fold changes between
VEGFδ/δ mice and their littermates were, in general,
Table 1: Primer pairs used for QPCR experiments
Gene symbol Forward sequence Reverse Sequence Optimal primer conc F/R (fmol)
3' Actin GCTCTGGCTCCTAGCACCAT AGCCACCGATCCACACAGAGT 300/300
HspB8 GGGCCTGCTCATCATCGA GAGGAAGCTCGTTGTTGAAGCT 300/300
Nme1 CGCAGAACTGGATCTATGAGTGA CCCCTGCCTGTGAGAACAA 300/300
Zfp101 GGATGAAATCCTGTTCCCATACAT TGTCCTGGATTAGATACTGTATTTTGATA 900/900
Fos ATTGTCGAGGTGGTCTGAATGTT AACGTTTTCATGGAAAACTGTTAATG 300/300
Rln AAGCACTCGCAAACAAAATTACAT CCTAAGCGACCTTCGTCTTCTG 900/900
HspA5 CCTCAGAGTGGAGTTGAAAATGCTA GACCCCAAGACATGTGAGCAA 300/900
Ldlr ACCTGGCTCGGTTTTCATTCT AGAGTATCACCCCAGCCTAACCT 900/900
Scd1 GACCAGTCAAAGTGCAAGACTACCTA AAGGTTTCCTGCAATGGTTTTC 300/300
Nrp1 CGGTAACAACAGGAATCATGTACAA TTACCCAAATGAAACCAAGAGAAGA 300/300
Mtap1B CCGTTGCACCTTTCGTAGCT AGCCAATGCAAGACAAAGGAA 100/100
Alcam GGACACATATCTTGCCCAATCAG ATCCTATGGTGCTCCTAACTCTCAA 300/900
HNRPDL TTGTAAAAGACTTTGTACTCTAGATCAGAGA TGGCAGCTATATAGACTTCCAGAGA 300/900
Tnrc6a ATGTTGGACACCGTAACCTAAGC TATGGACATCAACACACACCGAAT 300/300
VEGF ATGCTCCCCGGGGTGTAT CATAGGAGTCCTTCTGACCCATTC 600/600
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using the mutant SOD1 model of ALS [21].
Gene ontology analysis
Gene ontology (GO) terms which were significantly
enriched (at level p < 0.05) amongst genes significantly
differentially expressed between transgenic and wild type
mice were identified for each time point. Over-repre-
sented GO terms at each time point are given in Tables 3,
4 and 5. Four GO clusters were identified: Ontology
terms concerned with mitochondrial function and energy
production, with steroid metabolism, with axonogenesis
and nervous system development, and with gene expres-
sion and RNA metabolism. There is overlap between GO
terms enriched at 3 months and 5 months, and between 5
months and late stage disease, suggesting that the pro-
cesses represented by these terms are affected in trans-
genic mice in a sequential manner, as disease progresses.
Mitochondrial function and energy production
In presymptomatic mice, fewer transcriptional changes
were seen in transgenic mice, compared to their wild-
type littermates than at the other time points of disease.
The most significantly over-represented GO terms
related to cellular energy production (TCA cycle metabo-
lism, generation of precursor metabolites and energy and
carbohydrate metabolism). The differentially expressed
genes included several genes encoding TCA cycle
enzymes and components of the electron transport chain
(Table 6). Three genes encoding TCA cycle enzymes,
Mdh2, Ldh2 and Oxct1, are upregulated, while Ldh1, an
isoform that favours glycolysis over oxidative metabolism
[22], is downregulated. In the electron transport chain,
genes that produce components of 4 out of the 5 com-
plexes, and Pcdc8, which is required for mitochondrial
oxidative phosphorylation [23], show upregulation (Fig-
ure 3). These gene expression changes would be consis-
tent with a small but significant increase in oxidative
metabolism in neurones of VEGFδ/δ mice in the early
stages of disease. Concomitant with this increase, there
was upregulation of the free radical scavenging enzymes,
Prdx2 and Sod2.
Cholesterol metabolism
At disease onset, there was enrichment of genes assigned
GO terms relating to steroid metabolism, all of which
were downregulated (Table 7). These included five genes
that catalyse reactions in the final committed pathway to
cholesterol synthesis pathway (Figure 4). Sqle is a rate
limiting step in this pathway [24]. Prkaa2 is a catalytic
subunit of AMPK, which regulates HMG CoA reductase
activity. Ldlr and Sorl1 have similar functions in binding
LDL, the major cholesterol carrying lipoprotein of
plasma, and transporting it into cells. Hsd17b7 catalyses
the synthesis of steroid hormones from cholesterol, while
Stard4 promotes transport of cholesterol across the mito-
chondrial membrane, and stimulates steroidogenesis
[25]. Nr3c1 is the glucocorticoid receptor.
Nervous system development
At all stages of disease, there was differential expression
of genes involved in nervous system development, with
prominent enrichment of GO terms relating to nervous
system development in the significant gene lists at both 5
months and 14 months. Genes with functions relating to
nervous system development at these time points, the
majority of which are downregulated, are shown in Table
8 and Figure 5. Several are identified by more than one
probe set or at more than one time point.
There is downregulation in VEGFδ/δ mice of genes that
promote neurite outgrowth, such as Nrn1 [26], Slitrk1
[27], RasGrf1[28] and Serpine2, which is an inhibitor of
thrombin [29]. Thrombin causes neurite retraction and
neuronal death via its receptor F2r, which is upregulated
at 3 and 5 months [30]. Tsc1, which inhibits axon growth,
is also upregulated at both time points [31]. Growth fac-
tors such and NGF, BDNF, GDNF and TGFß2 promote
neuronal differentiation and outgrowth [32,33], There is
downregulation in motor neurones of VEGFδ/δ mice of
the BDNF receptor, Ntrk2, and its downstream mediator,
Tiam1 [34]; the GDNF receptor, Gfra1; several compo-
nents of the TGFß2 signaling pathway; and Lmtk2, a
mediator of NGF signalling [35]. Rufy3 is implicated in
the formation of a single axon, to determine neuronal
polarity [36]. Apbb2 interacts with amyloid precursor
protein, which is required for the maintenance of den-
Figure 2 Histogram of fold change values of significantly differ-
entially expressed genes at 3 months (green), 5 months (blue) 
and late stage (red). Upregulated genes are plotted on the positive 
axis, downregulated genes on the negative axis.
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with a key role in neuronal morphogenesis. Null muta-
tions in Klf7 lead to deficits in neuronal outgrowth and
axon guidance [38]. The Rho GTPase pathway controls
cytoskeletal reorganization to regulate neurone out-
growth, and the maturation and maintenance of dendritic
spines. The Rho GTPase, Rac, is activated by vav3 [39].
Cyfip1 interacts with Rac and null mutations lead to
defects in axon growth, guidance and branching, and in
the organization of the neuromuscular junction [40].
The GO category 'microtubule-based process' is over-
represented at 5 months, with downregulation of genes
that are assigned this function. Microtubules are promi-
nent elements of the neuronal cytoskeleton, involved in
the growth and maintenance of neurites, and along which
motor proteins move. Microtubule associated proteins
bind to the tubulin substrate that make up microtubules,
and regulate their stability [41]. Tubulin ß5 and three
microtubule associated proteins, Maptau, Mtap1b and
Mtap6, are downregulated in VEGFδ/δ mice, as are two
motor proteins, kinesin 2 and Dnclic2, and BICD2 which
binds cargoes to dynein. Disruption of the dynein-dynac-
tin pathway through prevention of BICD2 uncoupling
causes motor neurone degeneration in mice [42]. Ttl
causes post-translational modifications of αtubulin that
are essential to neurite extension and normal brain devel-
opment [43]. Tbce is a tubulin chaperone, required for
stabilization of neuronal processes, a mutation of which
causes the progressive motor neuronopathy of the pmn
mouse [44]. Dystonin is thought to have a role in
cytoskeletal cross-linking leading to axonal stability [45].
Differentially expressed genes in the VEGFδ/δ model
encode a number of proteins that mediate attractive and
repulsive growth cone signals during axonal guidance,
including Nrp1 and its ligand sema3A [46] and Nrp2 [47].
Two downregulated genes have regulatory functions in
the growth cone tip: Dpysl3 and DCAMKII [48,49].
Table 2: Numbers of significantly differentially expressed genes at each time point
3 months ALL FC >1.5 >2
PROBE SETS 
THAT PASS 
SIGNAL FILTER
UP DOWN UP DOWN UP DOWN
6563 p < 0.05 207 117 16 27 2 6
p < 0.01 26 28 6 9 1 2
p < 0.001 3 7 2 2 1 1
5 months ALL FC >1.5 >2
PROBE SETS 
THAT PASS 
SIGNAL FILTER
UP DOWN UP DOWN UP DOWN
7236 p < 0.05 73 311 10 138 2 23
p < 0.01 10 60 0 31 0 6
p < 0.001 1 5 0 3 0 1
14 months ALL FC >1.5 >2
PROBE SETS 
THAT PASS 
SIGNAL FILTER
UP DOWN UP DOWN UP DOWN
8200 p < 0.05 75 614 7 120 2 22
p < 0.01 10 146 2 57 0 12
p < 0.001 1 22 0 9 0 2
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dependent regulation of axonal growth, and in the con-
trol of neuronal migration. Fourteen adhesion molecules
and related molecules are downregulated in the VEGFδ/δ
mouse. Alcam is a member of the immunoglobulin super-
family which has a specific role in the guidance of motor
axons and formation of neuromuscular junctions (NMJs)
[50]. Both L1 and cd24 interact and cooperate with each
other as potent stimulators of neurite outgrowth [51].
Cd24, and Numb, which mediates endocytosis of the cell-
adhesion molecule L1 [52] are downregulated in VEGFδ/δ
mice. The DCC (deleted in colon cancer) subgroup of the
immunoglobulin superfamily are ligands for netrin, with
roles in the migration and guidance of axonal growth
cones. Igdcc4 is a newly recognized member of this
group, which is downregulated at 5 months [53], as is the
netrin Ntng1[54]. Both Pip5k1c and Astn1 are required
for normal neurone migration [55,56].
The formation of synapses involves guidance of axonal
processes towards target cells, target recognition, fol-
lowed by recruitment of pre- and post-synaptic elements.
The synaptic connections between motor neurones and
muscle exhibit both functional and anatomical plasticity
after maturation, with changes in synaptic strength, and
the formation and retraction of neuronal sprouts from
synaptic terminals or Nodes of Ranvier. This enables the
neuromuscular system to compensate for growth,
changes in muscle use, and damage or disease [57]. Adhe-
sion molecules play a central role in the formation and
plasticity of synapses, several of which are downregulated
in the VEGFδ/δ mouse, including two protocadherins;
cadherin 10 [58,59]; two members of the neurexin family,
Nrxn3 and Cntnap2, which bind postsynaptic neuroligins
[60,61]; and SynCAM, a member of the immunoglobulin
superfamily. Rnf6 binds to LIM kinase 1, which regulates
actin dynamics and is important in determining synaptic
structure [62]. Calcitonin-gene-related peptide, of which
both polypeptide chains are downregulated in the
VEGFδ/δ mouse, is released from motor neurones to stim-
ulate acetylcholine receptor synthesis by muscle, at the
NMJ [63]. Reelin is an extracellular matrix protein with a
well-recognized function in neuronal migration. More
recently, it has been shown to play a role in synaptic plas-
ticity [64], and in the maturation of synaptic contacts
during development, by refinement of NMDA-receptor
subunit composition [65]. The activation of downstream
signalling pathways of reelin is cholesterol-dependent
[66]. Fos and Jun form the heterodimer, AP-1, which plays
a central role in controlling development, growth, sur-
vival and plasticity of neurones. AP-1 has also been
shown to positively regulate synapse strength and num-
ber, acting upstream of CREB [67]. Both Fos and CREB
are downregulated in the VEGFδ/δ mouse.
Proteins of the canonical wingless signalling pathway
participate in the assembly of the NMJ, with crucial com-
ponents being the wingless co-receptor, arrow, Dishev-
elled and GSK3ß. GSK3ß functions by regulating the
structure of the microtubule cytoskeleton, probably via
the microtubule-associated protein, MAP1B. Mutations
in this pathway cause aberrant NMJ formation, with
reduction in number of synaptic boutons [68]. Dishev-
elled, GSK3ß and MAP1B are downregulated in the
Table 3: GO terms significantly enriched amongst differentially expressed genes at 3 months
Gene ontology term No. of genes Fold Enrichment p value
Energy production
tricarboxylic acid cycle 
intermediate metabolic 
process
4 9.8 0.0066
generation of precursor 
metabolites and energy
18 1.9 0.0128
Carbohydrate metabolic 
process
14 1.8 0.0454
Other
cardiac muscle cell 
differentiation
3 12.7 0.0212
striated muscle cell 
differentiation
4 6.2 0.0246
cardiac cell differentiation 3 9.8 0.0348
response to temperature 
stimulus
4 4.9 0.0454
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Gene ontology term No. of genes Fold Enrichment p value
Nervous system 
development
axon extension 6 8.1 0.0006
cell part morphogenesis 18 2.4 0.0010
cell projection organization 
and biogenesis
18 2.4 0.0010
cell projection 
morphogenesis
18 2.4 0.0010
regulation of axon extension 5 10.2 0.0010
regulation of axonogenesis 6 5.6 0.0035
regulation of neurogenesis 7 4.5 0.0040
cellular morphogenesis 
during differentiation
13 2.5 0.0055
positive regulation of cell 
adhesion
4 8.9 0.0087
axonogenesis 11 2.6 0.0090
neurite development 13 2.3 0.0093
nervous system development 27 1.7 0.0105
cell morphogenesis 23 1.7 0.0135
cellular structure 
morphogenesis
23 1.7 0.0135
neurite morphogenesis 11 2.4 0.0175
neuron morphogenesis 
during differentiation
11 2.4 0.0175
neuron development 13 2.1 0.0183
microtubule-based process 12 2.1 0.0249
negative regulation of axon 
extension
3 10.5 0.0304
neuron differentiation 14 1.9 0.0346
negative regulation of 
neurogenesis
4 5.4 0.0348
Neurogenesis 16 1.7 0.0403
cell migration 13 1.9 0.0413
generation of neurons 15 1.8 0.0457
negative regulation of 
axonogenesis
3 8.1 0.0493
Cholesterol metabolism
cholesterol metabolic process 7 3.9 0.0083
steroid biosynthetic process 8 4.3 0.0021
sterol biosynthetic process 6 5.9 0.0030
sterol metabolic process 8 3.9 0.0039
steroid metabolic process 10 2.9 0.0064
cholesterol biosynthetic 
process
5 6.1 0.0078
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dishevelled signalling pathway [69]. TGFß also plays role
in the development and functioning of synapses [70].
There is downregulation in the VEGFδ/δ mouse of TGFß2;
D0H4S114, which regulates TGF signalling [71]; Smad4
and ß-spectrin at disease onset, which associate in
response to TGFß, and are required for the assembly of
the NMJ [72,73].
Pre-synaptic proteins
Concomitant with the downregulation of genes involved
in the formation and morphological plasticity of syn-
apses, a reduction was seen in the expression of several
genes encoding proteins that comprise the pre-synaptic
machinery (Table 9), including several genes involved in
the fusion of synaptic vesicles, which is mediated by the
SNARE complex of VAMP/synaptobrevin, syntaxin and
SNAP25. Both VAMP3 and Napb were downregulated in
VEGFδ/δ mice, as was the syntaxin-binding protein,
Stxbp6; SytI1, one of a family of calcium-binding proteins
that need to be bound to the SNARE complex for pore
opening to occur; the SNAP associated protein, Snapap,
which enhances association of synaptotagmin with the
SNARE complex [74]; Unc13C which binds to and acti-
vates syntaxin [75]; gelsolin which disassembles the actin
network to liberate synaptic vesicles for release [76]; pic-
colo, which is a scaffolding protein involved in the organi-
zation of synaptic active zones, where synaptic vesicles
dock and fuse [77]; and synapsins I and II, which modu-
late neurotransmitter release, possibly by maintaining a
pool of synaptic vesicles near to the active zone [78]. PPI
controls activity of ion channels and signal transduction
enzymes to determine functional synaptic plasticity, and
downregulation of several of its regulatory and catalytic
subunits was seen, in addition to Phactr1 and 2, which
regulate PPI activity [79].
RNA processing
At late stage disease, GO terms related to gene expression
and its regulation are enriched amongst significantly dif-
ferentially expressed genes, including the sub-categories
of mRNA metabolism and processing, and RNA splicing
(Table 10). Of the 651 named genes differentially
expressed at 14 months, 143 (22%) have functions relat-
ing to gene expression, and of these, 132 (92%) are down-
regulated. This finding is interesting in light of the
massive transcriptional downregulation seen at late stage
disease.
Among the changes seen in this functionally category
of genes, was downregulation of a number of splicing fac-
tors, and other genes involved in mRNA processing. Sev-
eral ribosomal components also showed reduced
expression. The cAMP responsive element binding pro-
tein, CREB1 is a stimulus-inducible transcription factor
RNA metabolism
nuclear mRNA splicing, via 
spliceosome
7 3.4 0.0153
RNA splicing, via 
transesterification reactions
7 3.4 0.0153
Energy production
generation of precursor 
metabolites and energy
20 1.7 0.0282
Other
protein import 8 3.3 0.0106
leukocyte migration 4 8.1 0.0112
protein import into nucleus 7 3.6 0.0115
leukocyte migration 4 8.1 0.0112
protein import into nucleus 7 3.6 0.0115
nuclear import 7 3.5 0.0140
nucleocytoplasmic transport 9 2.5 0.0249
feeding behaviour 4 6.1 0.0253
nuclear transport 9 2.5 0.0265
alcohol metabolic process 14 1.9 0.0296
Table 4: GO terms significantly enriched amongst differentially expressed genes at 5 months (Continued)
Brockington et al. BMC Genomics 2010, 11:203
http://www.biomedcentral.com/1471-2164/11/203
Page 11 of 29
Table 5: GO terms significantly enriched amongst differentially expressed genes at 14 months
Gene ontology term No. of genes Fold Enrichment p value
RNA metabolism and 
regulation of gene 
expression
protein-RNA complex 
assembly
11 2.5 0.011
mRNA metabolic process 23 1.7 0.012
mRNA processing 21 1.8 0.014
gene expression 136 1.2 0.015
RNA splicing 18 1.8 0.018
Regulation of gene expression 98 1.2 0.024
Regulation of transcription 91 1.2 0.032
regulation of nucleoside, 
nucleotide and nucleic acid 
metabolic process
92 1.2 0.040
transcription 93 1.2 0.047
negative regulation of gene 
expression, epigenetic
4 4.7 0.048
Nervous system 
development
neurite morphogenesis 14 2.0 0.018
neuron morphogenesis 
during differentiation
14 2.0 0.018
axonogenesis 13 2.1 0.019
neurite development 15 1.8 0.037
cellular morphogenesis 
during differentiation
14 1.8 0.040
neuron development 16 1.7 0.045
Other
nuclear export 8 4.6 0.001
protein export from nucleus 5 6.9 0.004
negative regulation of 
metabolic process
23 1.6 0.029
phosphatidylinositol 
metabolic process
4 5.5 0.032
nucleocytoplasmic transport 11 2.1 0.034
macromolecule biosynthetic 
process
41 1.4 0.034
nuclear transport 11 2.1 0.036
negative regulation of cellular 
metabolic process
20 1.6 0.046
phospholipid metabolic 
process
11 2.0 0.047
heme metabolic process 4 4.7 0.048
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opment, function and plasticity of the nervous system
[80]. Downregulation of several members of the CREB
family is seen in VEGFδ/δ mice-CREB1, CREBBP, CREBzf,
its interacting partner, ATF4 (CREB2), and Cri2. Inactiva-
tion of neuronal CREB1 has been shown to cause defects
in neurone migration, similar to those observed with ree-
lin [81], and to stimulate neurodegeneration [82]. There
is also downregulation of the androgen receptor, and
related nuclear receptors, Nr1d2, Nr2c2 and the oestro-
gen receptor, Esrrg. Steroid hormones have wide ranging
effects on the structure and function of the nervous sys-
tem. Androgen receptor function is known to be impor-
tant for motor neurone survival, and disruption of this
function in Kennedy's disease contributes to the motor
neurone degeneration seen in this condition [83].
Verification of microarray results by QPCR
The results of QPCR verification for the 15 representative
genes chosen is shown in Table 11. Eight genes showed a
significant downregulation of expression in VEGFδ/δ
mice, which supported the microarray findings. A further
4 showed a trend towards downregulation which failed to
reach significance, while 4 showed no change in expres-
sion despite a finding of significant expression by
microarray analysis. The majority of microarray publica-
tions have indicated that arrays and QPCR analysis usu-
ally support each other qualitatively. However, it is well
recognized that significant quantitative differences occur
between microarray and QPCR data [84]. This may be
related to gene specific variation in the hybridization
kinetics associated with the two technologies, low fold
changes or hybridization signals in the microarray exper-
iment, or lack of transcript concordance between the
probes used for microarray and QPCR analysis. The pro-
portion of genes validated by this study using QPCR, with
the larger sample sizes at 3 and 5 months, is comparable
to that found by other studies [85,86]. Although not all
changes seen on microarray were validated by QPCR, it
has been argued that where the focus of microarray anal-
ysis is the overall pattern of gene expression rather than
the response of a few genes, as in this study, there is less
utility in confirming the expression differences of individ-
ual genes [87].
Reduced axon growth of VEGFδ/δ motor neurones grown in 
vitro
Downregulation of genes involved in nervous system
development and axonogenesis was observed in motor
neurones of VEGFδ/δ mice. A functional correlation of
this finding was demonstrated by the growth of primary
motor neurones from VEGFwt/wt, VEGFδ/wt and VEGFδ/δ
mice in vitro. Survival of primary motor neurone cultures
grown under basal conditions for 7 days was unaffected
by deletion of the hypoxia response element of the VEGF
gene (data not shown). A significant reduction in the
length of axons was observed in cultures of motor neu-
rones homozygous for the HRE deletion, compared to
Figure 3 Diagrammatic representation of the components of the mitochondrial electron transport chain, and the constituent proteins en-
coded by genes significantly upregulated in VEGFδ/δ mice.
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Table 6: Differentially regulated genes involved in cellular energy production at 3 months
Probe ID Gene title Symbol p value FC Regn
Electron transport chain
1438159 NADH 
dehydrogenase 
(ubiquinone) 
flavoprotein 2
Ndufv2 0.0330 1.15 up
1435757 Ubiquinol 
cytochrome C 
reductase core 
protein 2
Uqcrc2 0.0066 1.21 up
1456588 Cytochrome c 
oxidase, subunit 
Vb
Cox5b 0.0460 1.16 up
1450561 Surfeit gene 1 Surf1 0.0187 1.16 up
1449710 ATP synthase H+ 
transporting, 
mitochondrial F1 
complex, α 
subunit, isoform 1
Atp5a1 0.0216 1.09 up
1454661 ATP synthase H+ 
transporting, 
mitochondrial F0 
complex, subunit 
c, isoform 3
Atp5g3 0.0309 1.06 up
1418127 Programmed cell 
death 8 
(Apoptosis 
inducing factor)
Pcdc8 0.0185 1.26 up
TCA cycle
1419737 Lactate 
dehydrogenase 1, 
A chain
Ldh1 0.0077 1.86 down
1433984 Malate 
dehydrogenase 2, 
NAD
Mdh2 0.0188 1.16 up
1455235 Lactate 
dehydrogenase 2, 
B chain
Ldh2 0.0216 1.12 up
1436750 3-oxoacid CoA 
transferase1
Oxct1 0.0441 1.30 up
Free radical scavenging
1430979 Peroxiredoxin 2 Prdx2 0.0397 1.27 up
1444531 Superoxide 
dismutase 2, 
mitochondrial
Sod2 0.0417 1.20 up
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Page 14 of 29wild-type motor neurones (472 ± 26 μm vs 562 ± 31 μm,
p = 0.047; figure 6a). The outgrowth of dendrites was
unaffected (p = 0.34; figure 6b).
Discussion
Upregulation of oxidative phosphorylation in 
presymptomatic mice
A small but significant upregulation of genes involved in
the TCA cycle and oxidative phosphorylation was
observed in VEGFδ/δ mice in presymptomatic stages. This
finding is not in keeping with the 'chronic ischaemia'
hypothesis of neurodegeneration in the VEGFδ/δ mouse
model: were motor neurones in a state of chronic oxygen
deprivation due to reduced baseline neural blood flow,
oxidative phosphorylation would have been downregu-
lated. A similar upregulation of oxidative phosphoryla-
tion was seen in motor neurones in the SOD1 mouse
model of ALS [21], and this may be a non-specific adapta-
tion to cellular stress in the early stages of disease.
Transcriptional downregulation and changes in the 
regulation of gene expression
One of the most marked changes observed in the VEGFδ/
δ mouse model was transcriptional downregulation with
disease progression, which was accompanied in late stage
disease by a reduction in expression of genes involved in
the regulation of gene expression, particularly mRNA
processing. Similar transcriptional downregulation was
observed in a study of the SOD1 mouse model of ALS
[21], and in the ageing human brain [88]. The cause of
this transcriptional downregulation is not known,
although several mechanisms may be proposed. Firstly, it
Figure 4 Schematic representation of the cholesterol biosynthesis pathway, with genes that are differentially regulated in VEGFδ/δ mice at 
5 months highlighted in red. Cytochrome B5 reductase is an electron carrier for 5-desaturase and methyl sterol oxidase [119]
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DNA, which has been shown to accompany downregula-
tion of gene expression in the ageing human brain [88].
Secondly, reduction in expression of VEGF could result in
reduced induction of sequence-specific transcription fac-
tors, such as Fos, which was robustly downregulated in
this study, with consequent downregulation of genes reg-
ulated by those factors [89,90]. Thirdly, epigenetic modi-
fications which cause suppression of gene expression,
such as DNA methylation, increase with age and are
accelerated in neurodegenerative diseases [91].
Downregulation of cholesterol metabolism at disease 
onset
Five genes in the final committed pathway to cholesterol
synthesis, and two receptors which bind cholesterol and
transport it into the cells, were downregulated in the
VEGFδ/δ mouse. Neuronal cholesterol is either synthe-
sised by neurones or produced by astrocytes, bound to
apolipoprotein E (APOE), and taken up by neurones via
the low density lipoprotein receptor[92]. Cholesterol-rich
lipid rafts in the growth cone are required for down-
stream signaling of adhesion molecules and guidance
receptors during axon growth and guidance. Cholesterol
stimulates the formation of synapses, and has important
roles in synaptic function, and the release of neurotrans-
mitters [93-96]. A recent study showed that the neu-
rotrophic factor, BDNF, promotes synaptic development
in cortical neurones via the stimulation of cholesterol
biosynthesis [97], and the findings of this study suggest
that VEGF may have a similar function. Cholesterol
homeostasis is already implicated in the pathogenesis of
neurodegenerative disease. There is a strong association
between Alzheimer's disease and the APOE4 allele, which
has reduced efficacy in cholesterol delivery to cells, and
in stimulating neurite outgrowth [98]. Downregulation in
the expression of genes involved in the cholesterol syn-
thesis pathway is seen in cortical tissue of patients with
Table 7: Differentially expressed genes in the category of 'Steroid metabolism' at 5 months
Probe ID Gene Title Symbol p value FC Regn
1416222 NAD(P) 
dependent 
steroid 
dehydrogenase-
like
Nsdhl 0.0372 1.77 down
1421821 low density 
lipoprotein 
receptor
Ldlr 0.0172 2.13 down
1422185 cytochrome b5 
reductase 3
Cyb5r3 0.0248 2.24 down
1423078 sterol-C4-methyl 
oxidase-like
Sc4mol 0.0161 2.10 down
1429240 StAR-related lipid 
transfer (START) 
domain 
containing 4
Stard4 0.0044 1.83 down
1438322 farnesyl 
diphosphate 
farnesyl 
transferase 1
Fdft1 0.0442 1.56 down
1448130 farnesyl 
diphosphate 
farnesyl 
transferase 1
Fdft1 0.0323 1.86 down
1457248 hydroxysteroid 
(17-beta) 
dehydrogenase 7
Hsd17b7 0.0250 1.74 down
1460390 sortilin-related 
receptor, LDLR 
class A
Sorl1 0.0499 1.33 down
1415993 squalene 
epoxidase
Sqle 0.0204 1.97 down
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disease [99,100].
Neurite outgrowth and synaptogenesis
In adult mice, reduction in neural expression of VEGF,
through deletion of its hypoxia-response element, causes
downregulation of genes which are known to play a role
in the growth of neuronal processes and formation of
synapses during embryonic development. These include
promoters of outgrowth of neuronal processes, compo-
nents of neurotrophic signalling pathways, cell adhesion
molecules, and the cholesterol synthesis pathway. The
most significantly enriched functional gene categories at
5 months relate to axon extension and axon maintenance.
This finding was supported by in vitro data: primary
motor neurones from VEGFδ/δ mice show a significant
reduction in axon outgrowth compared to their wild-type
littermates. This effect of VEGF was specific to that neu-
ronal compartment, with no effect on dendrite growth, or
on cell survival. Exogenous VEGF protein stimulates
axon outgrowth in cultures of primary motor neurones
[20] although to a lesser degree than exogenous BDNF
and CNTF. Despite addition of BDNF and CNTF to the
primary neurone cultures in this study, axon outgrowth
from VEGFδ/δ motor neurones was significantly reduced,
indicating that the effect of VEGF on axonal outgrowth
cannot be substituted for by the presence of other growth
factors.
Differential expression of genes relating to the growth
of neuronal processes, and formation of synapses was an
unexpected finding in the adult animal, but there is grow-
ing evidence that changes involved in the plasticity of the
nervous system and in the maintenance of neuronal net-
works in the adult animal recapitulate, to some degree,
those underlying the formation of neuronal networks
Figure 5 Schematic representation of genes involved in neuronal migration, neurite outgrowth and formation and maintenance of the 
neuromuscular junction, which are all downregulated in the VEGF transgenic mouse.
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Page 17 of 29Table 8: Differentially expressed genes in the category of 'Nervous system development'
Probe ID Gene Title Symbol p value FC Regn Time point
Neurite outgrowth
1428393 neuritin 1 Nrn1 0.0090 3.82 down 14 months
1428089 SLIT and NTRK-like family, 
member 1
Slitrk1 0.0156 1.35 down 5 months
1416666 serine peptidase inhibitor, 
clade E, member 2
Serpine2 0.0414 1.65 down 5 months
1437308 coagulation factor II 
(thrombin) receptor
F2r 0.0346 1.59 up 3 months
1437308 coagulation factor II 
(thrombin) receptor
F2r 0.0286 1.22 up 5 months
1455252 tuberous sclerosis 1 Tsc1 0.0073 1.37 up 5 months
1422600 RAS protein-specific guanine 
nucleotide-releasing factor 1
Rasgrf1 0.0011 1.63 down 14 months
1435614 RAS protein-specific guanine 
nucleotide-releasing factor 1
Rasgrf1 0.0002 1.44 down 14 months
1455027 RUN and FYVE domain 
containing 2
Rufy3 0.0360 1.43 down 5 months
1424402 RUN and FYVE domain 
containing 2
Rufy3 0.0382 1.32 down 5 months
1452342 amyloid beta precursor 
protein-binding, family B, 
member 2
Apbb2 0.0415 1.21 down 14 months
1449439 Kruppel-like factor 7 
(ubiquitous)
Klf7 0.0008 1.62 down 5 months
Growth factor signalling pathways
1420838 neurotrophic tyrosine kinase, 
receptor, type 2
Ntrk2 0.0067 1.29 down 5 months
1418057 T-cell lymphoma invasion and 
metastasis 1
Tiam1 0.0006 1.66 down 5 months
1418057 T-cell lymphoma invasion and 
metastasis 1
Tiam1 0.0031 1.43 down 14 months
1439015 glial cell line derived 
neurotrophic factor receptor 
alpha 1
Gfra1 0.0454 1.95 down 5 months
1455018 lemur tyrosine kinase 2 Lmtk2 0.0107 1.32 down 14 months
TGFß signalling pathway
1450923 transforming growth factor, 
beta 2
Tgfb2 0.0397 1.47 down 5 months
1450839 DNA segment, human D4S114 D0H4S114 0.0093 2.00 down 3 months
1450839 DNA segment, human D4S114 D0H4S114 0.0190 1.98 down 5 months
1450839 DNA segment, human D4S114 D0H4S114 0.0025 1.50 down 14 months
1422487 MAD homolog 4 (Drosophila) Smad4 0.0368 1.41 down 5 months
1452143 spectrin beta 2 Spnb2 0.0023 1.21 down 5 months
1425116 spectrin beta 4 Spnb4 0.0463 1.14 up 14 months
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1416329 cytoplasmic FMR1 interacting 
protein 1
Cyfip1 0.0158 1.36 down 5 months
1448600 vav 3 oncogene Vav3 0.0304 1.32 down 5 months
Microtubule-based processes
1455719 tubulin, beta 5 Tubb5 0.0034 1.60 down 5 months
1421851 microtubule-associated 
protein 1 B
Mtap1b 0.0142 2.10 down 5 months
1457316 microtubule-associated 
protein 6
Mtap6 0.0105 1.75 down 5 months
1424719 microtubule-associated 
protein tau
Mapt 0.0482 1.50 down 5 months
1417005 kinesin 2 Kns2 0.0484 1.17 down 5 months
1433926 dynein, cytoplasmic, light 
intermediate chain 2
Dnclic2 0.0121 1.36 down 5 months
1437875 bicaudal D homolog 2 Bicd2 0.0236 1.45 down 5 months
1451630 tubulin tyrosine ligase Ttl 0.0016 1.45 down 5 months
1428282 tubulin-specific chaperone e Tbce 0.0348 1.24 down 14 months
1423626 dystonin Dst 0.0358 1.24 down 5 months
Axon guidance
1418084 neuropilin 1 Nrp1 0.0092 2.02 down 5 months
1448944 neuropilin 1 Nrp1 0.0151 1.58 down 5 months
1456778 neuropilin 2 Nrp2 0.0020 1.28 down 5 months
1420416 semaphorin 3A Sema3a 0.0010 1.35 down 5 months
1420416 semaphorin 3A Sema3a 0.0341 1.26 down 14 months
1415877 dihydropyrimidinase-like 3 Dpysl3 0.0461 2.25 down 5 months
1450863 double cortin and 
calcium/calmodulin-
dependent protein 
kinase-like 1
Dcamkl1 0.0364 1.29 down 5 months
Synapse formation and plasticity
1427898 ring finger protein (C3H2C3 
type) 6
Rnf6 0.0182 1.59 down 5 months
1452004 calcitonin-related polypeptide, 
alpha
Calca 0.0283 1.26 down 5 months
1422639 calcitonin-related polypeptide, 
beta
Calcb 0.0389 1.78 down 5 months
1449465 reelin Reln 0.0006 2.38 down 3 months
1423100 FBJ osteosarcoma oncogene Fos 0.0313 2.32 down 3 months
1423100 FBJ osteosarcoma oncogene Fos 0.0123 2.17 down 5 months
1452901 cAMP responsive element 
binding protein 1
Creb1 0.0148 1.44 down 14 months
Table 8: Differentially expressed genes in the category of 'Nervous system development' (Continued)
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1437301 dishevelled, dsh homolog 1 
(Drosophila)
Dvl1 0.0166 1.38 down 14 months
1434439 glycogen synthase kinase 3 
beta
Gsk3b 0.0023 1.23 down 14 months
1437351 CXXC finger 4 Cxxc4 0.0462 1.37 down 5 months
1437351 CXXC finger 4 Cxxc4 0.0341 1.30 down 14 months
Cell adhesion molecules
1437466 activated leukocyte cell 
adhesion molecule
Alcam 0.0329 1.94 down 5 months
1437467 activated leukocyte cell 
adhesion molecule
Alcam 0.0233 1.60 down 5 months
1437466 activated leukocyte cell 
adhesion molecule
Alcam 0.0400 1.65 down 14 months
1426301 activated leukocyte cell 
adhesion molecule
Alcam 0.0045 1.51 down 14 months
1437467 activated leukocyte cell 
adhesion molecule
Alcam 0.0414 1.50 down 14 months
1416034 CD24a antigen Cd24a 0.0165 1.96 down 5 months
1416891 numb gene homolog 
(Drosophila)
Numb 0.0394 1.45 down 14 months
1424954 phosphatidylinositol-4-
phosphate 5-kinase, type 1 
gamma
Pip5k1c 0.0166 1.14 down 14 months
1418615 astrotactin 1 Astn1 0.0461 1.65 down 5 months
1416474 immunoglobulin superfamily, 
DCC subclass, member 4
Igdcc4 0.0342 1.19 down 5 months
1449286 netrin G1 Ntng1 0.0119 1.87 down 14 months
1442659 protocadherin 9 Pcdh9 0.0166 1.64 down 14 months
1420429 protocadherin beta 3 Pcdhb3 0.0365 1.89 down 14 months
1425092 cadherin 10 Cdh10 0.0208 1.39 down 14 months
1433788 neurexin III Nrxn3 0.0021 1.78 down 14 months
1422798 contactin associated protein-
like 2
Cntnap2 0.0077 1.37 down 5 months
1417378 synaptic cell adhesion 
molecule
Syncam 0.0400 1.40 down 14 months
1417377 synaptic cell adhesion 
molecule
Syncam 0.0191 1.38 down 14 months
1422445 integrin alpha 6 Itga6 0.0221 1.50 down 5 months
Others
1457015 Neurofilament 3, medium Nef3 0.0209 1.40 up 14 months
1416533 EGL nine homolog 2 Egln2 0.0203 1.46 down 5 months
1420475 myotrophin Mtpn 0.0120 1.67 down 5 months
1417133 peripheral myelin protein Pmp22 0.0159 1.89 down 5 months
1449353 wild-type p53-induced gene 1 Wig1 0.0249 1.57 down 5 months
1417624 Ngfi-A binding protein 1 Nab1 0.0119 1.44 down 5 months
Table 8: Differentially expressed genes in the category of 'Nervous system development' (Continued)
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ate target recognition and synapse formation during
embryogenesis also lead to changes in synaptic efficacy in
the adult nervous system [101]; BMP signalling at the
Drosophila NMJ is not only required for normal synaptic
growth, but also for synaptic stabilization, via LIM
kinase-1, and disruption of this pathway leads to synaptic
disassembly and retraction [102]; the wnt signalling path-
way maintains activity-dependent axon stability in adult
olfactory neurones [103]; neurotrophins were first recog-
nized as target-dependent survival factors for developing
neurones during embryogenesis, but they have also been
shown to promote synaptic stability and maintain neu-
ronal processes in response to mechanical axonal injury
[104].
Although the NMJ is considered a relatively stable
structure, plasticity of the motor system is seen in
response to changing physiological demands and to path-
ological conditions. Alterations in synaptic structure and
function occur in the motor cortex, spinal cord and NMJ
in response to exercise [105-107], while partial denerva-
tion or paralysis results in sprouting and reinnervation
from adjacent nerve fibres [57]. The observation of fibre-
type grouping in ageing muscle indicates that denerva-
tion and reinnervation of muscle fibres occurs with nor-
mal ageing [108]. Motor units differ in the plasticity of
their synapses. Synapses formed on Fast Synapsing
(FaSyn) muscle, or by fast-fatiguable (FF)-type motor
units exhibit relatively little synaptic plasticity, compared
to Delayed Synapsing (DeSyn) or slow (S)-type motor
units. Motor units with less synaptic plasticity exhibit
early susceptibility to loss in motor neurone degenerative
disease, and in the SOD1 mouse model of ALS, a progres-
sive impairment of stimulus-induced synaptic sprouting
was observed over the course of the disease, suggesting
that the absence of synaptic plasticity, and disease-
induced synaptic loss are mechanistically linked
[109,110].
The transcriptional changes observed in VEGFδ/δ mice
would be predicted to result in a reduced capacity for the
morphological adaptations that occur during plasticity of
the motor unit, resulting in increased vulnerability to
degeneration. As neuronal processes and synapses are
required continuously to retract and reform during the
process of synaptic plasticity, downregulation of genes
involved in neurite growth and synapse formation would
be likely to result in gradual attrition of synapses and dis-
tal cellular processes. Synapse retraction causes loss of
access of the neurone to trophic signals from target tis-
sue. A recent study has shown that muscle hypermetabo-
lism is sufficient to cause degeneration of NMJs, and
subsequent loss of spinal cord motor neurones [111].
Although ALS is characterized pathologically by loss of
motor neurone somata, and gliosis in the anterior horn of
the spinal cord, these post mortem findings may not
reflect changes occurring earlier in the disease. There is
evidence in both human ALS and in mouse models, that
motor neurone death occurs by the type of 'dying back'
axonal degenerative pathophysiology, that would be pre-
dicted in this model, with defects of neuromuscular
transmission, end-plate denervation, and 'peripheral
pruning' of axons as the earliest observed events [112-
114]. VEGFδ/δ mice similarly show relative preservation
of spinal motor neurones, at stages of disease where there
is marked axonal loss [1].
The relevance of this finding in the VEGFδ/δ mouse
model of ALS to the human disease is unknown, but fail-
ure of synaptic plasticity has been proposed as a patho-
genic mechanism in Alzheimer's disease [115]. A failure
to maintain neuronal processes and synapses in the face
of increasing demands of neuronal plasticity would
explain two epidemiological observations in ALS: the
associations between exposure to vigorous physical activ-
ity [116,117] or skeletal fractures [118], and the risk of
developing the disease.
An alternative hypothesis is that the pathogenic insult
in VEGFδ/δ mice occurs during their development, when
a lack of VEGF may lead to aberrant neuronal guidance
and formation of neural networks. Subtle defects in neu-
ronal positioning and in synaptic circuitry in VEGFδ/δ
mice could result in reduced stability of synaptic connec-
tions, or a reduction in target-derived neurotrophic sup-
port, with consequent increased loss of motor neurones
during ageing. This hypothesis is supported by the obser-
vation that embryonic motor neurones show a reduction
in axonal outgrowth in vitro.
Conclusions
Reduction in expression of VEGF, through deletion of a
regulatory promoter region of the gene, results in adult-
onset motor neurone degeneration that resembles human
ALS. We have presented evidence here that this pheno-
type is accompanied by reduction in expression, from
symptom onset, of the cholesterol synthesis pathway, and
genes involved in nervous system development, including
axonogenesis, synapse formation, growth factor signal-
ling pathways, cell adhesion and microtubule-based pro-
cesses. These findings raise the possibility that VEGF is
required for the maintenance of distal neuronal processes
in the adult animal, perhaps through promotion of
remodelling of distal processes and synapses in the face of
the demands of neuronal plasticity. A reduction in VEGF
expression in VEGFδ/δ mice may lead to failure of the
maintenance of neuronal circuitry, causing axonal retrac-
tion and cell death.
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Table 9: Genes encoding presynaptic proteins, differentially expressed in VEGFδ/δ mice
Probe ID Gene name Symbol p value FC Reg Time point
1456245 vesicle-associated 
membrane protein 3
Vamp3 0.0159 1.47 down 14 months
1423173 N-ethylmaleimide 
sensitive fusion 
protein ß
Napb 0.0021 1.59 down 14 months
1423172 N-ethylmaleimide 
sensitive fusion 
protein ß
Napb 0.0024 1.55 down 14 months
1433788 N-ethylmaleimide 
sensitive fusion 
protein ß
Napb 0.0021 1.78 down 14 months
1435396 syntaxin binding 
protein 6
Stxbp6 0.0290 1.46 down 5 months
1435396 syntaxin binding 
protein 6
Stxbp6 0.0179 1.33 down 14 months
1429314 synaptotagmin XI Syt11 0.0274 1.47 down 5 months
1415756 SNAP-associated 
protein
Snapap 0.0058 1.70 down 5 months
1455304 unc-13 homolog C Unc13c 0.0070 2.86 down 14 months
1436991 gelsolin Gsn 0.0092 1.62 down 5 months
1419392 piccolo Pclo 0.0267 1.47 down 14 months
1451484 synapsin I Syn1 0.0098 1.49 down 5 months
1435511 synapsin II Syn2 0.0146 1.74 down 5 months
1435667 regulating synaptic 
membrane exocytosis 1
Rims1 0.0370 1.32 up 3 months
1422880 synaptophysin-like 
protein
Sypl 0.0384 1.15 down 3 months
1417919 protein phosphatase 1, 
regulatory subunit 7
Ppp1r7 0.0256 1.30 down 5 months
1433691 protein phosphatase 1, 
regulatory subunit 3C
Ppp1r3c 0.0218 1.49 down 5 months
1440285 protein phosphatase 1, 
regulatory subunit 9A
Ppp1r9a 0.0063 1.24 down 5 months
1452046 protein phosphatase 1, 
catalytic subunit, 
gamma
Ppp1cc 0.0276 1.38 down 5 months
1434895 protein phosphatase 1, 
regulatory subunit 13B
Ppp1r13b 0.0280 1.32 down 14 months
1456072 protein phosphatase 1, 
regulatory subunit 9A
Ppp1r9a 0.0217 1.32 down 14 months
1440285 protein phosphatase 1, 
regulatory subunit 9A
Ppp1r9a 0.0304 1.22 down 14 months
1420734 protein phosphatase 1, 
regulatory subunit 3F
Ppp1r3f 0.0102 1.17 down 14 months
1456606 phosphatase and actin 
regulator 1
Phactr1 0.0196 1.35 down 5 months
1455101 phosphatase and actin 
regulator 2
Phactr2 0.0489 1.66 down 5 months
1455101 phosphatase and actin 
regulator 2
Phactr2 0.0463 1.41 down 14 months
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Probe ID Gene Title Symbol p value FC Regn
1437984 HLA-B-associated transcript 1A Bat1a 0.0101 1.18 down
1436549 heterogeneous nuclear ribonucleoprotein A1 Hnrpa1 0.0354 1.30 down
1452712 heterogeneous nuclear ribonucleoprotein A3 Hnrpa3 0.0176 1.47 down
1423873 LSM1 homolog, U6 small nuclear RNA associated Lsm1 0.0450 1.19 down
1434704 myeloid/lymphoid or mixed-lineage leukaemia 5 Mll5 0.0024 1.66 down
1424136 peptidyl prolyl isomerase H Ppih 0.0123 1.40 down
1451909 PRP4 pre-mRNA processing factor 4 homolog B Prpf4b 0.0366 1.38 down
1438420 RNA-binding region (RNP1, RRM) containing 2 Rnpc2 0.0004 1.76 down
1459765 splicing factor 1 Sf1 0.0405 1.34 down
1436898 splicing factor proline/glutamine rich Sfpq 0.0101 1.88 down
1416151 splicing factor, arginine/serine-rich 3 Sfrs3 0.0305 1.24 down
1423130 splicing factor, arginine/serine-rich 5 Sfrs5 0.0494 1.59 down
1416721 splicing factor, arginine/serine-rich 6 Sfrs6 0.0232 1.26 down
1424033 splicing factor, arginine/serine-rich 7 Sfrs7 0.0264 1.30 down
1437180 small nuclear ribonucleoprotein 48 Snrnp48 0.0285 1.68 down
1437007 ubiquitin specific peptidase 39 Usp39 0.0047 1.33 down
1450845 basic leucine zipper and W2 domains 1 Bzw1 0.0269 1.27 up
1437841 cold shock domain containing C2, RNA binding Csdc2 0.0130 1.43 up
1415920 cleavage stimulation factor, 3' pre-RNA subunit 2, 
tau
Cstf2t 0.0092 1.27 down
1437071 eukaryotic translation initiation factor 1A, Y-linked Eif1ay 0.0281 1.21 down
1434538 eukaryotic translation initiation factor 2B, subunit 
2 beta
Eif2b2 0.0149 1.23 down
1454664 eukaryotic translation initiation factor 5 Eif5 0.0439 1.12 down
1424252 heterogeneous nuclear ribonucleoprotein D-like Hnrpdl 0.0046 2.20 down
1415911 imprinted and ancient Impact 0.0009 1.47 down
1451125 poly(A) binding protein interacting protein 2B Paip2b 0.0327 1.14 down
1424216 poly (A) polymerase alpha Papola 0.0286 1.55 down
1427544 poly (A) polymerase alpha Papola 0.0305 1.22 down
1436586 ribosomal protein S14 Rps14 0.0321 1.25 down
1416065 ankyrin repeat domain 10 Ankrd10 0.0494 1.27 down
1435307 ankyrin repeat domain 34B Ankrd34B 0.0154 5.84 down
1452342 amyloid beta (A4) precursor protein-binding, 
family B, member 2
Apbb2 0.0415 1.21 down
1455647 androgen receptor Ar 0.0248 1.30 down
1420985 ash1 (absent, small, or homeotic)-like Ash1l 0.0413 1.23 down
1450072 ash1 (absent, small, or homeotic)-like Ash1l 0.0416 1.22 down
1449947 AT motif binding factor 1 Atbf1 0.0213 1.49 down
1438992 activating transcription factor 4 Atf4 0.0069 1.35 down
1418271 basic helix-loop-helix domain containing, class B5 Bhlhb5 0.0456 1.69 down
1452850 breast cancer metastasis-suppressor 1-like Brms1l 0.0371 1.28 down
1435445 cyclin T2 Ccnt2 0.0159 1.52 down
1420497 CCAAT/enhancer binding protein zeta Cebpz 0.0435 1.28 down
1454641 CGG triplet repeat binding protein 1 Cggbp1 0.0063 1.42 down
1434002 checkpoint supressor 1 Ches1 0.0452 1.37 down
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1436980 CCR4-NOT transcription complex, subunit 2 Cnot2 0.0089 1.36 down
1456576 CCR4-NOT transcription complex, subunit 2 Cnot2 0.0046 1.31 down
1437982 COX15 homolog, cytochrome c oxidase assembly 
protein
Cox15 0.0406 1.14 up
1452901 cAMP responsive element binding protein 1 Creb1 0.0148 1.44 down
1436983 CREB binding protein Crebbp 0.0428 1.23 down
1452857 CREB/ATF bZIP transcription factor Crebzf 0.0245 1.45 down
1454931 CREBBP/EP300 inhibitory protein 2 Cri2 0.0384 1.24 down
1429618 cylindromatosis (turban tumor syndrome) Cyld 0.0025 1.55 down
1448234 DnaJ (Hsp40) homolog, subfamily B, member 6 Dnajb6 0.0214 1.23 down
1459805 dihydrouridine synthase 3-like Dus3l 0.0103 1.39 down
1418850 enhancer of polycomb homolog 1 Epc1 0.0133 1.23 down
1455267 estrogen-related receptor gamma Esrrg 0.0026 1.50 down
1456615 fetal Alzheimer antigen Falz 0.0130 1.33 down
1423709 phenylalanine-tRNA synthetase-like, beta subunit Farslb 0.0270 1.34 down
1459861 F-box and leucine-rich repeat protein 10 Fbxl10 0.0052 1.32 down
1428890 fem-1 homolog c Fem1c 0.0498 1.22 down
1417113 germ cell-less homolog Gcl 0.0341 1.31 down
1424296 glutamate-cysteine ligase, catalytic subunit Gclc 0.0143 1.38 down
1448381 G elongation factor 1 Gfm1 0.0045 1.35 down
1437163 general transcription factor II H, polypeptide 4 Gtf2h4 0.0446 1.17 up
1425628 transcription factor TFII-I-alpha Gtf2i 0.0296 1.32 down
1416176 high mobility group box 1 Hmgb1 0.0077 1.29 down
1455626 homeo box A9 Hoxa9 0.0190 1.61 down
1454760 HIV TAT specific factor 1 Htatsf1 0.0337 1.28 down
1460669 interleukin enhancer binding factor 3 Ilf3 0.0213 1.27 down
1455762 kinase D-interacting substrate 220 Kidins220 0.0152 1.26 down
1456341 Kruppel-like factor 9 Klf9 0.0080 1.38 down
1455214 microphthalmia-associated transcription factor Mitf 0.0081 1.30 down
1435547 MKL/myocardin-like 2 Mkl2 0.0335 1.35 down
1443500 myeloid/lymphoid or mixed lineage-leukemia 
translocation to 10
Mllt10 0.0080 1.16 up
1457632 myeloid ecotropic viral integration site-related 
gene 1
Mrg1 0.0333 2.40 down
1424204 mitochondrial ribosomal protein L13 Mrpl13 0.0101 1.24 down
1434971 mitochondrial ribosomal protein L15 Mrpl15 0.0463 1.13 down
1440989 mitochondrial ribosomal protein L35 Mrpl15 0.0041 1.35 down
1456109 mitochondrial ribosomal protein S15 Mrps15 0.0311 1.30 down
1452608 c-myc binding protein Mycbp 0.0004 1.47 down
1423201 nuclear receptor co-repressor 1 Ncor1 0.0107 1.26 down
1447693 Neogenin Neo1 0.0410 1.18 down
1448963 nuclear transcription factor-Y gamma Nfyc 0.0215 1.19 down
1434398 NF-kappaB repressing factor Nkrf 0.0074 1.71 down
1419112 nemo like kinase Nlk 0.0478 1.27 down
1416958 nuclear receptor subfamily 1, group D, member 2 Nr1d2 0.0079 1.57 down
1454851 nuclear receptor subfamily 2, group C, member 2 Nr2c2 0.0491 1.15 down
Table 10: Differentially expressed genes in the category 'Gene expression' (Continued)
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Page 24 of 291448493 polyadenylate-binding protein-interacting 
protein 2
Paip2 0.0261 1.42 down
1426878 polybromo1 Pbrm1 0.0033 1.22 down
1427266 polybromo1 Pbrm1 0.0046 1.31 down
1417493 polycomb group ring finger 4 Pcgf4 0.0091 1.24 down
1453271 PHD finger protein 14 Phf14 0.0151 1.52 down
1456395 peroxisome proliferative activated receptor, γ, 
coactivator 1a
Ppargc1a 0.0001 1.66 down
1456037 prolactin regulatory element binding Preb 0.0147 1.41 down
1428254 purine rich element binding protein B Purb 0.0102 1.29 down
1436979 RNA binding motif protein 14 Rbm14 0.0106 1.19 down
1422660 RNA binding motif protein 3 Rbm3 0.0398 1.54 up
1443922 REST corepressor 3 (Rcor3), mRNA Rcor3 0.0495 1.32 up
1434521 regulatory factor X domain containing 2 homolog Rfxdc2 0.0103 1.39 down
1438505 ribonuclease III, nuclear Rnasen 0.0341 1.14 down
1426660 ribosomal protein L23a Rpl23a 0.0332 1.26 down
1437975 ribosomal protein L23a Rpl23a 0.0488 1.18 down
1436046 ribosomal protein L29 Rpl29 0.0144 1.15 down
1448846 ribosomal protein L29 Rpl29 0.0314 1.20 down
1454627 ribosomal protein L29 Rpl29 0.0113 1.38 down
1455348 ribosomal protein L29 Rpl29 0.0203 1.21 down
1420381 ribosomal protein L31 Rpl31 0.0134 1.40 down
1438986 ribosomal protein S17 Rps17 0.0496 1.24 down
1430288 ribosomal protein S21 Rps21 0.0471 1.19 down
1415876 ribosomal protein S26 Rps26 0.0311 1.33 down
1423763 ribosomal protein S28 Rps28 0.0406 1.15 down
1435816 ribosomal protein S6 Rps6 0.0011 1.15 up
1448584 arginine/serine-rich coiled-coil 1 Rsrc1 0.0148 1.25 down
1428219 RING1 and YY1 binding protein Rybp 0.0223 1.46 down
1416008 special AT-rich sequence binding protein 1 Satb1 0.0242 1.28 down
1417892 sirtuin 3 (silent mating type information regulation 
2, homolog) 3
Sirt3 0.0200 1.27 down
1426668 solute carrier family 30 (zinc transporter), 
member 9
Slc30a9 0.0325 1.34 down
1429624 SAFB-like transcription modulator Sltm 0.0193 1.21 down
1436703 small nuclear RNA activating complex, 
polypeptide 2
Snapc2 0.0432 1.14 up
1444531 Superoxide dismutase 2, mitochondrial Sod2 0.0254 1.21 up
1451542 single-stranded DNA binding protein 2 Ssbp2 0.0262 1.40 down
1434238 RNA polymerase II, TATA box binding protein-
associated factor
Taf2 0.0063 1.54 down
1436318 TAR DNA binding protein Tardbp 0.0104 1.60 down
1452593 transcription elongation factor B (SIII), 
polypeptide 1
Tceb1 0.0360 1.15 up
1421147 telomeric repeat binding factor 2 Terf2 0.0355 1.24 down
1460545 thyroid hormone receptor associated protein 3 Thrap3 0.0201 1.11 down
1416812 cytotoxic granule-associated RNA binding 
protein 1
Tia1 0.0287 1.47 down
Table 10: Differentially expressed genes in the category 'Gene expression' (Continued)
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Page 25 of 291416814 cytotoxic granule-associated RNA binding 
protein 1
Tia1 0.0115 1.50 down
1434898 trinucleotide repeat containing 6a Tnrc6a 0.0004 1.57 down
1434899 trinucleotide repeat containing 6a Tnrc6a 0.0039 1.43 down
1438376 tripartite motif protein 27 Trim27 0.0415 1.15 down
1426954 tripartite motif protein 33 Trim33 0.0320 1.27 down
1447780 Tu translation elongation factor, mitochondrial Tufm 0.0433 1.16 down
1435389 ubiquitin A-52 residue ribosomal protein fusion 
product 1
Uba52 0.0105 1.35 down
1455222 upstream binding protein 1 Ubp1 0.0403 1.35 down
1427097 WW domain containing E3 ubiquitin protein 
ligase 1
Wwp1 0.0464 1.25 down
1420011 X-box binding protein 1 Xbp1 0.0167 1.24 down
1437223 X-box binding protein 1 Xbp1 0.0496 1.33 down
1422569 YY1 transcription factor Yy1 0.0313 1.35 down
1457285 zinc finger protein 187 Zfp187 0.0332 1.20 down
1426895 zinc finger protein 191 Zfp191 0.0081 1.18 down
1456824 zinc finger protein 612 Zfp612 0.0388 1.16 down
1437873 zinc finger protein 799 Zfp799 0.0078 1.48 down
1448875 zinc fingers and homeoboxes protein 1 Zhx1 0.0471 1.18 down
1426531 zinc finger, MYND domain containing 11 Zmynd11 0.0005 1.32 down
Table 10: Differentially expressed genes in the category 'Gene expression' (Continued)Table 11: Comparison of QPCR and microarray data of the 15 genes selected for verification
Microarray result QPCR result
Time point Gene Symbol FC P value n FC P value
3 months Zfp101 +4.35 0.01 6 No change
Fos -2.32 0.03 6 -2.59 0.0003
Reelin -1.88 0.004 6 -1.68 0.03
HspA5 -1.44 to -1.46 0.02 to 0.01 6 -1.34 0.06
5 months Fos -2.17 0.01 6 -2.13 0.0007
Ldlr -2.14 0.02 6 -1.42 0.006
Scd1 -2.07 0.02 6 -1.19 0.01
Nrp1 -1.58 to -2.02 0.02 to 0.009 6 No change
Mtap1B -2.10 0.01 6 No change
Alcam -1.60 to -1.94 0.03 to 0.02 6 -1.43 0.01
14 months Reelin -2.41 0.007 3 -2.1 0.008
HSPA5 -1.48 0.004 3 -1.27 0.2
Hnrpdl -2.20 0.005 3 -1.21 0.2
Tnrc6a -1.43 to -1.57 0.004 to 0.0004 3 No change
Alcam -1.50 to -1.65 0.04 to 0.004 3 -1.59 0.003
Significant results are highlighted in bold; n = no. of transgenic mice used for QPCR verification, with an equal number of gender matched 
littermate controls.
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